- Trial phase
- Phase 3
- Time to market
- If the Phase 3 TRANSCEND data (expected H1 2027) are positive, a regulatory filing could follow in 2027-2028, with potential FDA decision in 2028-2029 at the earliest. For IgA nephropathy, a Phase 3 program would likely be needed, extending the timeline further. Felzartamab is still investigational with no regulatory submissions filed yet.
- Why 6/10
- The next hard, dated catalyst is the Phase 3 TRANSCEND topline data readout in antibody-mediated rejection (AMR), expected in H1 2027 (~6-9 months from now). Felzartamab is a meaningful pipeline asset in Biogen's expanding nephrology franchise, but Biogen is a large-cap company with multiple approved products (LEQEMBI, EMPAVELI, TECFIDERA) totaling ~$37B market cap, so this single drug is not make-or-break.
Watch for the Phase 3 TRANSCEND topline data expected H1 2027, positive results would be a meaningful pipeline catalyst for BIIB but not transformative given the company's scale. Investors should monitor for any early signals on efficacy from conference presentations and analyst previews in the months leading up to the readout. The competitive landscape in AMR (imlifidase, complement inhibitors, CAR-T) also warrants attention as it could narrow felzartamab's potential market.
Price Chart
Executive Summary
Felzartamab is Biogen's investigational anti-CD38 antibody targeting antibody-mediated rejection (AMR) in kidney transplant and other immune-mediated kidney diseases. The drug is in a single Phase 3 trial (TRANSCEND, n=132) with topline data expected in H1 2027. While the unmet need in chronic AMR is large and no approved therapy exists, felzartamab is just one pipeline asset at a large-cap biotech with a broad portfolio, limiting single-drug stock impact. The Phase 3 readout is the next binary catalyst, but with results 6-9 months away and a small trial size, the risk/reward is balanced for equity investors.
How It Works
Felzartamab is an antibody that targets CD38, a protein found on the surface of plasma cells, the immune cells that produce antibodies. In kidney transplant rejection, the body's plasma cells make 'donor-specific antibodies' that attack the transplanted organ. Felzartamab depletes these plasma cells, reducing the harmful antibodies and potentially stopping the rejection process.
Trial Status
The Phase 3 TRANSCEND study (NCT06685757, n=132) for antibody-mediated rejection (AMR) in kidney transplant recipients is fully enrolled and active but not recruiting. Estimated primary completion is December 2026, with final completion in June 2027. A Phase 2 study in IgA nephropathy (NCT05065970, n=54) has been completed with results available. Biogen has consolidated global rights via the HI-Bio acquisition (2024) and a separate Greater China rights deal with TJ Biopharma in April 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 TRANSCEND topline data readout in antibody-mediated rejection (AMR), expected H1 2027
- ASN Kidney Week presentations (ongoing) highlighting felzartamab data across multiple kidney disease indications
- Any potential initiation of Phase 3 trials in IgA nephropathy following Phase 2 completion
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Biogen Inc. Press Release BIIB ·Originating report